Emerging Agents Reshaping the ITP Landscape

The FDA’s August 2025 approval of rilzabrutinib, a BTK inhibitor, represents a paradigm shift for individuals with ITP following insufficient response to previous treatments. This novel therapeutic approach addresses multiple unmet needs by targeting the fundamental autoimmune mechanisms driving ITP rather than simply managing symptoms or stimulating platelet production through traditional pathways.

ITP pathophysiology involves complex immune dysregulation where patients develop elevated pro-inflammatory cytokines (IL-2, interferon-g, IL-17) alongside reduced regulatory cytokines (IL-10, transforming growth factor-b). This imbalance triggers autoantibody production, specifically IgG antibodies that target platelet surface glycoproteins like GP2B3A and GP1B9, leading to platelet destruction in the spleen through Fc-greceptor–mediated phagocytosis. These autoantibodies also impair platelet production by inhibiting megakaryocyte maturation and platelet formation in bone marrow. B-cell dysregulation further amplifies this autoantibody overproduction, creating a self-perpetuating inflammatory cycle.

BTK inhibition offers mechanistic advantages by targeting this intracellular protein expressed in B cells, macrophages, and platelets. By disrupting BTK signaling, rilzabrutinib modulates the dysregulated immune response and reduces pro-inflammatory cytokine production, including the NLRP3 inflammasome. This multitargeted immunomodulation represents a fundamental departure from existing therapies, potentially addressing not only platelet destruction but also the systemic inflammation believed to contribute to quality-of-life impairments, particularly the debilitating fatigue experienced by individuals living with ITP.